君實生物(01877.HK)擬採納A股限制性股票激勵計劃
君實生物(01877.HK)(688180.SH)公布,建議股東採納2022年A股限制性股票激勵計劃,涉及不逾1,332.5萬股A股,佔公司已發行A股總數約1.93%,及已發行股本總額約1.46%。首次授予的授予價格為每股70元人民幣(下同),合計不超過9.33億元,公司擬將所得款項應用於補充集團的流動資金。
公司指出,首次授予建議的激勵對象共計33人,佔集團於3月底僱員總數3,085人的約1.07%,當中,擬向執行董事、聯席首席執行官李聰,以及副總經理兼全球研發總裁鄒建軍各授出300萬股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.